Alicyclic Acids Having An Element Other Than Oxygen, Carbon, Or Hydrogen Patents (Class 562/507)
-
Publication number: 20080269517Abstract: A process for the preparation of acid halides of formula I which are useful as intermediates in the preparation of i.a. pharmaceutically active compounds.Type: ApplicationFiled: April 18, 2008Publication date: October 30, 2008Inventor: Ursula Hoffmann
-
Patent number: 7442834Abstract: This invention relates to an improved process for the preparation of substantially pure, stable anhydrous gabapentin. Thus, cyclohexane 1,1-diacetic acid monoamide is first treated with NaOH/NaClO to form 3,3-pentamethylenebutyrolactam, which is treated with aqueous HCl solution under reflux to provide gabapentin HCl salt, which is then neutralized with NaOH followed by a dehydration step to provide substantially pure, storage-stable, pharmaceutical grade gabapentin.Type: GrantFiled: July 12, 2006Date of Patent: October 28, 2008Assignee: Zhejiang Chiral Medicine Chemicals Co., Ltd.Inventors: Tianchun Liu, Youming Huang, Weirong Fan
-
Publication number: 20080262264Abstract: Disclosed is a process for the preparation of Compound (III), salt or solvate thereof by reacting Compound (I), salt or solvate thereof with Compound (II) in a toluene solvent in the presence of an additive such as water or an alcohol. Also disclosed is a process for the preparation of Compound (IV) comprising hydrolyzing the obtained Compound (III) if necessary, and then oxidizing. In the formula, R1 is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or optionally substituted aryl lower alkyl, and R2 is optionally substituted lower alkyl, optionally substituted cycloalkyl or optionally substituted aryl lower alkyl.Type: ApplicationFiled: March 30, 2006Publication date: October 23, 2008Applicant: Shionogi & Co., Ltd.Inventors: Toshiaki Masui, Kazuhiro Yoshida
-
Patent number: 7439387Abstract: The present invention relates to a new industrial feasible process for the preparation of Gabapentin Form-II via a novel intermediate Gabapentin hemisulphate hemihydrate with out forming Gabapentin Form-III by neutralizing the Gabapentin hemisulphate hemihydrate solution with a base at higher temperatures followed by cooling to yield Gabapentin Form II with sulphate ions less than 100 ppm with respect to Gabapentin.Type: GrantFiled: April 16, 2004Date of Patent: October 21, 2008Assignee: Matrix Laboratories Ltd.Inventors: Chava Satyanarayana, Gorantla Seeta Ramanjaneyulu, Indukuri Venkata Sunil Kumar
-
Publication number: 20080242728Abstract: The present invention relates to pharmaceutical compositions of gabapentin tannate in solid dosage form, processes for production of those compositions and methods of use of those compositions. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.Type: ApplicationFiled: June 13, 2008Publication date: October 2, 2008Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
-
Publication number: 20080226716Abstract: Compounds that provide for sustained systemic concentrations of GABA analogs following oral administration to animals are disclosed. Pharmaceutical compositions including, and methods using, such compounds are also disclosed.Type: ApplicationFiled: May 28, 2008Publication date: September 18, 2008Applicant: XenoPortInventors: Mark Gallop, Kenneth C. Cundy, Randall A. Scheuerman, Ronald W. Barrett, Noa Zerangue
-
Patent number: 7419981Abstract: The instant invention relates to a combination of an alpha-2-delta ligand and a PDEV inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. A particularly preferred PDEV inhibitors is sildenafil.Type: GrantFiled: February 3, 2004Date of Patent: September 2, 2008Assignee: Pfizer Inc.Inventors: Mark John Field, Richard Griffith Williams
-
Publication number: 20080207945Abstract: This invention relates to an efficient process for converting gabapentin hydrochloride salt to gabapentin by liquid-liquid extraction using a counter-current extraction method.Type: ApplicationFiled: February 28, 2008Publication date: August 28, 2008Inventors: Ziv Dee-Noor, Amir Gold
-
Patent number: 7417166Abstract: The present invention relates to a process for the preparation of gabapentin and, more particularly, it relates to a precipitation process of gabapentin by acidification of an aqueous solution deriving from the Hofmann rearrangement of 1,1-cyclohexanediacetic acid monoamide.Type: GrantFiled: March 21, 2005Date of Patent: August 26, 2008Assignee: Zach System S.p.A.Inventors: Roberto Giovanetti, Andrea Nicoli, Massimo Verzini, Giorgio Soriato, Livius Cotarca
-
Publication number: 20080199887Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.Type: ApplicationFiled: February 15, 2008Publication date: August 21, 2008Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
-
Publication number: 20080159954Abstract: The invention relates to the subjects characterized in the patent claims, namely metal chelates having a perfluorinated PEG radical, processes for their preparation, and their use, processes for their preparation and their use in NMR and X-ray diagnosis, radiodiagnosis and radiotherapy, and in MRT lymphography.Type: ApplicationFiled: October 17, 2007Publication date: July 3, 2008Inventors: Johannes Platzek, Heiko Schirmer, Hanns-Joachim Weinmann, Bernd Misselwitz, Ludwig Zorn
-
Patent number: 7393974Abstract: A conversion process of gabapentin hydrochloride into gabapentin comprising: a) dissolution of gabapentin hydrochloride in a solvent in which the gabapentin hydrochloride and the gabapentin are completely soluble; and b) subsequent addition of an amine that allows the removal of the chloride ion from the solution containing gabapentin hydrochloride, by precipitation of the hydrochloride of the same amine, leaving the gabapentin in solution in free amino acid form.Type: GrantFiled: November 29, 2001Date of Patent: July 1, 2008Assignee: Erregierre S.p.A.Inventors: Massimo Ferrari, Marcello Ghezzi, Paolo Belotti
-
Patent number: 7393975Abstract: A process for the preparation of gabapentin which comprises the passage of a gabapentin inorganic salt through a strong cationic ionic exchange resin, the elution of gabapentin fixed on the column, the concentration of the resultant solution and the cristallization from organic solvent, characterized in that the elution of gabapentin fixed on the column is carried out by using an ammonia and alkaline hydroxide aqueous solution, is described.Type: GrantFiled: June 17, 2004Date of Patent: July 1, 2008Assignee: ZACH System S.p.A.Inventors: Livius Cotarca, Roberto Giovanetti, Andrea Nicoli
-
Patent number: 7390922Abstract: The present invention relates to pharmaceutical compositions of gabapentin tannate, processes for production of those compositions and methods of use of those compositions. The present invention provides a novel process for preparation of the tannate salt of gabapentin in liquid or semi-solid dosage form for human and veterinary pharmaceutical use. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.Type: GrantFiled: March 22, 2004Date of Patent: June 24, 2008Assignee: Kiel Laboratories, Inc.Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
-
Patent number: 7381823Abstract: A new process is described for synthesising cyclohexanediacetic acid monoamide, a key compound in the synthesis of grabapentin precursors. The process of the invention is characterised by reacting cyclohexanone with cynoacetamide and immediately after, with a suitable malonic acid ester. A new intermediate (5-cyano-2,4-dioxo-3-azaspiro[5,5]undecane-1-carboxylic acid ester) is obtained which is convertible, under mild reaction conditions, into cyclohexanediacetic acid monoamide.Type: GrantFiled: March 17, 2005Date of Patent: June 3, 2008Assignee: Serichim S.R.L.Inventors: Bruno Danieli, Pietro Delogu, Sabrina De Rosa, Lorenza Fugazza
-
Publication number: 20080103334Abstract: A process for preparation of gabapentin comprising a step of obtaining 1,1-cyclohexane diacetic acid monoamide from 1,1-cyclohexane diacetic acid anhydride, wherein said reaction is characterized by the use of ammonia precursor or pre-generated ammonia-isopropanol solution. The invention further discloses preparation of gabapentin and isolation of gabapentin in polymorphic Form II with high yield and purity.Type: ApplicationFiled: October 24, 2007Publication date: May 1, 2008Applicant: IPCA Laboratories LtdInventors: Ashok Kumar, Satish Rajanikant Soudagar, Avinash Manohar Nijasure, Nalinakshya Balaram Panda, Prashant Gautam, Gajendrasingh Ramsingh Thakur
-
Patent number: 7365227Abstract: A process for the purification of gabapentin by treatment of a crude aqueous gabapentin hydrochloride solution with a strong cationic ion exchange resin.Type: GrantFiled: March 28, 2006Date of Patent: April 29, 2008Assignee: ZACH System S.p.A.Inventors: Vincenzo Cannata, Andrea Nicoli, Francesco Corcella
-
Patent number: 7365226Abstract: A process for the preparation of gabapentin comprising the passage of a salt of the same through a ionic exchange resin of strong cationic type, the elution of the gabapentin which has fixed onto the column and the crystallization from organic solvent, characterized in that the resin is regenerated by using a mineral acid in a molar quantity between 50 and 90%, is described.Type: GrantFiled: December 14, 2004Date of Patent: April 29, 2008Assignee: Zach System S.p.A.Inventors: Roberto Giovanetti, Andrea Nicoli, Angelo Restelli, Livius Cotarca
-
Publication number: 20080097122Abstract: The present invention relates to a process for the preparation of gabapentin and, more in particular, to a method of synthesis of 1,1-cyclohexane acetic acid monoamide, an intermediate used in the preparation of gabapentin, comprising the basic hydrolysis reaction of ?,?-diaminocarbonyl-?,?-pentamethylene glutarimide.Type: ApplicationFiled: June 22, 2005Publication date: April 24, 2008Applicant: AAMBON GROUPS P.P.A.Inventors: Marco Villa, Maurizio Paiocchi, Katiuscia Arrighi, Francesco Corcella, Vincenzo Cannata, Giorgio Soriato, Massimo Verzini
-
Publication number: 20080039527Abstract: The present invention provides compounds useful in inhibiting protein kinase B (PKB/Akt). Compositions comprising such compounds and their use are also provided.Type: ApplicationFiled: September 9, 2004Publication date: February 14, 2008Inventors: Rudiger Woscholski, Helen Claire Hailes, Macba Golda Numbere
-
Publication number: 20070287861Abstract: This invention relates to an improved process for the preparation of substantially pure, stable anhydrous gabapentin. Thus, cyclohexane 1,1-diacetic acid monoamide is first treated with NaOH/NaClO to form 3,3-pentamethylenebutyrolactam, which is treated with aqueous HCl solution under reflux to provide gabapentin HCl salt, which is then neutralized with NaOH followed by a dehydration step to provide substantially pure, storage-stable, pharmaceutical grade gabapentin.Type: ApplicationFiled: July 12, 2006Publication date: December 13, 2007Inventors: Tianchun Liu, Youming Huang, Weirong Fan
-
Publication number: 20070161818Abstract: Processes for producing shikimic acid through extraction from sweetgum, pine and cedar plant tissues and the shikimic acid produced by such processes.Type: ApplicationFiled: January 6, 2006Publication date: July 12, 2007Inventors: Shiyou Li, Wei Yuan, Ping Wang, Zhizhen Zhang, Wanli Zhang, Stacy Ownby
-
Patent number: 7199266Abstract: A process for the purification of gabapentin by treatment of a crude aqueous gabapentin hydrochloride solution with a strong cationic ion exchange resin.Type: GrantFiled: October 15, 2001Date of Patent: April 3, 2007Assignee: Zambon Group S.p.A.Inventors: Vincenzo Cannata, Andrea Nicoli, Francesco Corcella
-
Patent number: 7196216Abstract: A process for producing gabapentin, (1-(aminomethyl)-1-cyclohexaneacetic acid) from gabapentin hydrochloride salt. In the disclosed process, the gabapentin hydrochloride is converted to gabapentin using an inorganic base, such as barium hydroxide. Gabapentin hydrochloride is converted to gabapentin sulfate which in turn is converted to free base using barium hydroxide. The process is directed to improvement in the manufacture of gabapentin which would be industrially feasible and effective. Gabapentin obtained following the process of the invention is suitable as a drug especially in the treatment of cerebral diseases such as epilepsy.Type: GrantFiled: November 18, 2002Date of Patent: March 27, 2007Assignee: Nicholas Piramal India LimitedInventors: Jagdish Chand Saigal, Rajender Pershad Gupta, Rajesh Vinodrai Naik, Araddy Rajshekhar, Rajesh Dilip Joshi
-
Patent number: 7173151Abstract: The invention relates to arylcycloalkyl-substituted derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.Type: GrantFiled: February 27, 2004Date of Patent: February 6, 2007Assignee: Sanofi-AventisDeutschand GmbHInventors: Christian Stapper, Heiner Glombik, Eugen Falk, Dirk Gretzke, Jochen Goerlitzer, Stefanie Keil, Hans-Ludwig Schaefer, Wolfgang Wendler
-
Patent number: 7151193Abstract: Pure gabapentin form II can be directly obtained adding the solution of the corresponding hydrochloride in dry ethanol (from which the inorganic salts have been filtered off) with a tertiary amine and a small amount of water.Type: GrantFiled: February 3, 2004Date of Patent: December 19, 2006Assignee: Farchemia s.r.l.Inventors: Gabriele Breviglieri, Sergio Contrini, Cinzia Assanelli
-
Patent number: 7148377Abstract: The invention relates to novel 4-alkoxy-cyclohexane-1-amino-carboxylic esters of the formula (IV) in which R1 represents OR3, R2 represents alkyl, and R3 represents alkyl, to intermediates and processes for their preparation, and to their use as intermediates in the synthesis of insecticidal, acaricidal, and herbicidal compounds or pharmaceutically active compounds.Type: GrantFiled: June 22, 2001Date of Patent: December 12, 2006Assignee: Bayer CropScience AGInventors: Thomas Himmler, Reiner Fischer, Bernd Gallenkamp, Hans-Joachim Knops, Lubbertus Mulder
-
Patent number: 7141695Abstract: The invention relates to methods for producing substituted acrylic acid esters and to the use of the latter for producing substituted ?-amino acids, such as gabapentin and pregabalin. The substituted acrylic acid esters are produced by Wadsworth-Emmons olefination with trialkyl phosphonoacetate in the presence of alkali carbonate as the base, in an aqueous solvent.Type: GrantFiled: July 19, 2004Date of Patent: November 28, 2006Assignee: Grunenthal GmbHInventors: Michael Thomas Przewosny, Claudia Pütz
-
Patent number: 7138542Abstract: The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.Type: GrantFiled: December 21, 2005Date of Patent: November 21, 2006Assignee: Warner Lambert CompanyInventors: David James Dooley, David Juergen Wustrow
-
Patent number: 7109383Abstract: The invention relates to a fluorine-containing allyl ether compound represented by the formula 1, wherein R represents an organic group containing at least one fluorine atom and an alicyclic structure. The invention further relates to a fluorine-containing copolymer containing a first unit derived from the fluorine-containing allyl ether represented by the formula 1; and a second unit derived from a vinyl monomer.Type: GrantFiled: September 26, 2003Date of Patent: September 19, 2006Assignee: Central Glass Company, LimitedInventors: Satoru Kobayashi, Katsunori Kawamura, Kazuhiro Yamanaka, Haruhiko Komoriya, Kazuhiko Maeda
-
Patent number: 7098361Abstract: This invention is a family of ?,? amino acids based on 1,4 substituted rigid ring structures and the useful polyamides made from them.Type: GrantFiled: November 24, 2003Date of Patent: August 29, 2006Inventor: Donald H. Martin
-
Patent number: 7098362Abstract: The present invention relates to new processes for the preparation of gabapentin by the desilylation of a silylated gabapentin or by the silylation-desilylation of an acid addition salt of gabapentin with a silylating agent.Type: GrantFiled: July 19, 2005Date of Patent: August 29, 2006Assignee: Sandoz AGInventors: Rafael Garcia, Johannes Ludescher, Jordi Rifa, José Diago
-
Patent number: 7071356Abstract: A method of producing gabapentin (1-amino-methyl)-1-cyclohexaneacetic acid) from its hydrochloric salt in an anhydrous medium, the method consisting of: dissolving gabapentin hydrochloride in a non-aqueous organic solvent in which gabapentin is insoluble to obtain a solution of gabapentin hydrochloride; adding an epoxide to the solution to remove the chloride ions thereby precipitating gabapentin out of the solution as a white solid; recovering the white solid by filtration; and drying the white solid.Type: GrantFiled: December 1, 2005Date of Patent: July 4, 2006Assignee: ISP Investments Inc.Inventors: Satish C. Nigam, Krishnamurthy Nacharaju, Christophe Buron
-
Patent number: 7045655Abstract: The invention relates to the preparation of ultra-high purity 1,2-diaminocyclohexane-tetraacetic acid being essentially free of unwanted metal and metal ion contaminants and its use as a stabilizer for ultra-high purity hydroxylamine compounds used extensively in the production of high premium electronic components.Type: GrantFiled: December 10, 2003Date of Patent: May 16, 2006Assignee: BASF AktiengesellschaftInventors: Irl E. Ward, Danielle French
-
Patent number: 7030154Abstract: A method of stabilizing R-?-lipoic acid includes combining R-?-lipoic acid with nicotinamide in a weight ratio between about 10:4 to about 10:8. A composition for treating oxidative stress includes R-?-lipoic acid and nicotinamide in a weight ratio of between about 10:4 and about 10:8.Type: GrantFiled: June 5, 2003Date of Patent: April 18, 2006Assignee: Juvenon, Inc.Inventor: Bruce N. Ames
-
Patent number: 7026505Abstract: The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.Type: GrantFiled: January 29, 2003Date of Patent: April 11, 2006Assignee: Warner-Lambert CompanyInventors: David James Dooley, David Juergen Wustrow
-
Patent number: 7022678Abstract: In accordance with the present invention, there is provided pregabalin lactose conjugate compounds. Also provided as part of the present invention is a novel method of central nervous system disorders or diseases including seizure disorders, pain, depression, anxiety, sleep disorders, consumptive disorders, psychosis, tardive dyskinesia, Huntington's disease, or Parkinson's disease in a subject by administering to the subject a pharmaceutically effective amount of a pregabalin lactose conjugate.Type: GrantFiled: January 28, 2002Date of Patent: April 4, 2006Assignee: Warner-Lambert CompanyInventors: Timothy Robert Hurley, Michael James Lovdahl, Brian Tobias
-
Patent number: 6984496Abstract: An assay and method for selecting analogs and derivatives of gabapentin based on the compounds inhibitory activity toward MAP kinase and MAP kinase mediated reporter gene expression. The method includes the steps of activating the MAP kinase signaling pathway, detecting the MAP kinase signal, and screening the gabapentin analogs and derivatives for inhibitory activity against the MAP kinase signal.Type: GrantFiled: January 24, 2002Date of Patent: January 10, 2006Assignee: Warner-Lambert CompanyInventors: Fu-Zon Chung, Yulong Hong
-
Patent number: 6909014Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: September 5, 2003Date of Patent: June 21, 2005Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 6884821Abstract: Novel carboxylic acid derivatives of general formula (I), salts of the same, esters thereof, or hydrates of them, which are useful as insulin resistance improvers; and drugs containing the derivatives as the active ingredient. In said formula, R1 is hydrogen, hydroxyl, alkyl, or the like; L is a single bond, a double bond, alkylene, or the like; M is a single bond, alkylene, or the like; T is a single bond, alkylene, or the like; W is carboxyl, —CON(RW1)RW2, or the like; represents a single or double bond; X is oxygen, alkenylene, or the like; Y is an aromatic hydrocarbon group which may contain a heteroatom, or the like; and Z is an aromatic hydrocarbon group which may contain a heteroatom.Type: GrantFiled: September 29, 2000Date of Patent: April 26, 2005Assignee: Eisai Co., Ltd.Inventors: Masanobu Shinoda, Eita Emori, Fumiyoshi Matsuura, Toshihiko Kaneko, Norihito Ohi, Shunji Kasai, Hideki Yoshitomi, Kazuto Yamazaki, Sadakazu Miyashita, Taro Hibara, Takashi Seiki, Richard Clark, Hitoshi Harada
-
Patent number: 6867327Abstract: The invention relates to the preparation of ultra-high purity 1,2-diaminocyclohexanetetraacetic acid being essentially free of unwanted metal and metal ion contaminants and its use as a stabilizer for ultra-high purity hydroxylamine compounds used extensively in the production of high premium electronic components.Type: GrantFiled: December 16, 2002Date of Patent: March 15, 2005Assignee: BASF AktiengesellschaftInventors: Irl E. Ward, Danielle Anne French
-
Patent number: 6855832Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.Type: GrantFiled: October 11, 2002Date of Patent: February 15, 2005Assignee: Allergan, Inc.Inventors: Vidyasagar Vuligonda, Min Teng, Richard L. Beard, Alan T. Johnson, Yuan Lin, Roshantha A. Chandraratna
-
Patent number: 6846950Abstract: A process for synthesis of 1-(aminomethyl)cyclohexane acetic acid hydrochloride (Gabapentin hydrochloride) comprising: a) Reaction of a mixture of acetic anhydride/ammonium acetate with 1,1-cyclohexane-diacetic acid to yield 3,3-pentamethylene glutarimide; b) Treatment of 3,3-pentamethylene glutarimide with sodium hydroxide in an aqueous solution up to dissolution, dripping the solution thus obtained into a sodium hydroxide/sodium hypochlorite mixture, which is also aqueous, followed by acidification with hydrochloric acid to yield gabapentine hydrochloride.Type: GrantFiled: April 22, 2003Date of Patent: January 25, 2005Assignee: Erregierre S.p.A.Inventors: Massimo Ferrari, Marcello Ghezzi, Paolo Belotti
-
Publication number: 20040220261Abstract: The invention relates to arylcycloalkyl-substituted derivatives and to their physiologically acceptable salts and physiologically functional derivatives.Type: ApplicationFiled: February 27, 2004Publication date: November 4, 2004Applicant: Aventis Pharma Deutschland GmbHInventors: Christian Stapper, Heiner Glombik, Eugen Falk, Dirk Gretzke, Jochen Goerlitzer, Stefanie Keil, Hans-Ludwig Schaefer, Wolfgang Wendler
-
Publication number: 20040214893Abstract: The present invention comprises an organic acid salt of gabapentin, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid. Methods for modulating the solubility and dose response of gabapentin are discussed. Methods of making organic acid salts of gabapentin are also discussed.Type: ApplicationFiled: April 8, 2004Publication date: October 28, 2004Inventors: Matthew Peterson, Mark Oliveira
-
Patent number: 6809207Abstract: The present invention provides certain alpha-amino acids and derivatives thereof, such as, but not limited to, esters, amides and salts. These derivatives may comprise such representative side groups as a phenyl, pyridyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, or thienyl group. The present invention further provides a method for synthesizing alpha-amino acids and derivatives thereof via a modified Ugi type reaction using an aldehyde, ammonium formate and a C1-C5 alkyl isocyanide. The compounds provided by this method are useful in the development of new pharmaceuticals for the treatment of human diseases.Type: GrantFiled: July 24, 2002Date of Patent: October 26, 2004Assignee: PharmaCore, Inc.Inventors: Sekar Alla, Seung-Yong Choi, Dale Dhanoa, Elso DiFranco, Galina Krokhina, Keqiang Li, Balasubramanian Thiagarajan, Wen-Chun Zhang
-
Patent number: 6794433Abstract: Compounds and compositions comprising specific metal salts of hexahydrophthalic acid (HHPA) in order to provide highly desirable properties within thermoplastic articles are provided. The inventive HHPA derivatives are useful as nucleating and/or clarifying agents for such thermoplastics, are practical and easy to handle. Such compounds provide excellent crystallization temperatures, stiffness, and acid scavenger compatibility within target polyolefins. Also, such compounds exhibit very low hygroscopicity and therefore excellent shelf stability as powdered or granular formulations. Thermoplastic additive compositions and methods of producing polymers with such compounds are also contemplated within this invention.Type: GrantFiled: December 28, 2002Date of Patent: September 21, 2004Assignee: Milliken & CompanyInventors: Darin L. Dotson, X. Edward Zhao
-
Patent number: 6794164Abstract: This invention is directed to the use of crystallization acids, such as acetic, lactic and propionic acids, to obtain high purity polyhydroxyl cyclic carboxylic acids (PCCA) from low purity aqueous solutions. The preferred PCCA is shikimic acid and the preferred crystallization acid is acetic acid. The method according to the invention is particularly applicable to the isolation of shikimic acid from a fermentation broth.Type: GrantFiled: January 7, 2002Date of Patent: September 21, 2004Assignee: Novozymes Biopharma ABInventors: Mats Malmberg, Brita Westrup
-
Publication number: 20040180401Abstract: The present invention discloses methods of determining highly precise interactions between the HERG ion channel and various compounds. The methods of the present invention utilize the nonsense codon suppression methods combined with heterologous in vivo expression in Xenopus oocytes.Type: ApplicationFiled: May 23, 2003Publication date: September 16, 2004Applicant: Neurion Pharmaceuticals, Inc.Inventors: Dennis A. Dougherty, Henry A. Lester, Jonathan G. Lasch
-
Patent number: 6790986Abstract: Gabapentin free from mineral acids anions is obtained by precipitating from a gabapentin aqueous solution a corresponding hydroxybenzoate, from which pure gabapentin is subsequently obtained by dissolution in a lower alcohol and treatment with a tertiary base.Type: GrantFiled: May 27, 2003Date of Patent: September 14, 2004Assignee: Farchemia S.r.l.Inventors: Gabriele Breviglieri, Sergio Contrini, Cinzia Assanelli